# Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

> **NCT05330143** · PHASE2 · COMPLETED · sponsor: **Ascletis Pharmaceuticals Co., Ltd.** · enrollment: 19 (actual)

## Conditions studied

- HIV-1-infection
- HIV Infections
- PD-L1 Gene Mutation

## Interventions

- **DRUG:** ASC22 1mg/kg
- **DRUG:** ASC22 2.5mg/kg
- **DRUG:** Antiretroviral Therapy
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05330143
- **Lead sponsor:** Ascletis Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-28
- **Primary completion:** 2024-05-15
- **Final completion:** 2024-05-15
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05330143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05330143, "Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05330143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*